Trials / Completed
CompletedNCT02183376
Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects
Pharmacokinetics and Pharmacodynamics of BI 1356 5 mg Once Daily in Male and Female Subjects With Different Degrees of Liver Impairment (Child Pugh Classification A-C) as Compared to Male and Female Healthy Subjects (a Non-blinded, Parallel Group Study of Phase I)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
To investigate the influence of mild, moderate, and severe liver impairment on the pharmacokinetics and pharmacodynamics of linagliptin in comparison with a control group with normal hepatic function after single or multiple oral administration of 5 mg linagliptin tablets
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1356 |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2009-03-01
- First posted
- 2014-07-08
- Last updated
- 2014-07-08
Source: ClinicalTrials.gov record NCT02183376. Inclusion in this directory is not an endorsement.